See more : Sociedade Comercial Orey Antunes, S.A. (ORE.LS) Income Statement Analysis – Financial Results
Complete financial analysis of Vetnostrum Animal Health Co., Ltd. (6936.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vetnostrum Animal Health Co., Ltd., a leading company in the Agricultural Farm Products industry within the Consumer Defensive sector.
- Fun Yours Technology Co.,Ltd. (6482.TWO) Income Statement Analysis – Financial Results
- Living Cell Technologies Limited (LCT.AX) Income Statement Analysis – Financial Results
- JC Finance&Tax Interconnect Holdings Ltd. (002530.SZ) Income Statement Analysis – Financial Results
- The Orissa Minerals Development Company Limited (ORISSAMINE.NS) Income Statement Analysis – Financial Results
- Pointerra Limited (3DP.AX) Income Statement Analysis – Financial Results
Vetnostrum Animal Health Co., Ltd. (6936.TWO)
About Vetnostrum Animal Health Co., Ltd.
Vetnostrum Animal Health Co., Ltd. engages in the production and sale of animal health products in Taiwan and the Asia Pacific. It offers antibiotics, hormonal preparations, topical disinfectants, and drugs for anti-inflammatory, deworming, anti-fungal, antiprotozoal, etc; vitamins, minerals, and amino acids for regular supplementary; and non-medicated feed additives for swine, cattle and sheep, poultry, pet, and aquatic animals. The company is based in Taichung, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.21B | 1.19B | 1.18B | 1.11B | 1.08B |
| Cost of Revenue | 850.75M | 832.13M | 819.06M | 762.63M | 750.09M |
| Gross Profit | 356.76M | 353.23M | 357.16M | 342.50M | 330.34M |
| Gross Profit Ratio | 29.55% | 29.80% | 30.37% | 30.99% | 30.58% |
| Research & Development | 25.46M | 19.51M | 20.75M | 14.04M | 11.50M |
| General & Administrative | 73.35M | 70.01M | 64.73M | 61.86M | 56.27M |
| Selling & Marketing | 146.51M | 139.08M | 132.75M | 131.78M | 129.47M |
| SG&A | 219.87M | 209.09M | 197.48M | 193.63M | 185.74M |
| Other Expenses | 111.44M | 9.18M | -656.00K | -1.71M | 0.00 |
| Operating Expenses | 356.76M | 228.60M | 218.23M | 207.68M | 197.24M |
| Cost & Expenses | 1.21B | 1.06B | 1.04B | 970.30M | 947.32M |
| Interest Income | 541.00K | 135.00K | 41.00K | 97.00K | 151.00K |
| Interest Expense | 1.97M | 2.92M | 2.43M | 2.18M | 1.97M |
| Depreciation & Amortization | 76.74M | 78.22M | 77.44M | 64.53M | 46.40M |
| EBITDA | 191.74M | 212.15M | 213.43M | 197.63M | 194.07M |
| EBITDA Ratio | 15.88% | 17.90% | 18.34% | 17.89% | 17.96% |
| Operating Income | 114.90M | 133.94M | 138.32M | 133.21M | 133.10M |
| Operating Income Ratio | 9.52% | 11.30% | 11.76% | 12.05% | 12.32% |
| Total Other Income/Expenses | -1.87M | -2.93M | -4.76M | -2.30M | 12.61M |
| Income Before Tax | 113.03M | 131.01M | 133.56M | 130.91M | 145.71M |
| Income Before Tax Ratio | 9.36% | 11.05% | 11.36% | 11.85% | 13.49% |
| Income Tax Expense | 21.43M | 24.50M | 23.66M | 27.22M | 33.31M |
| Net Income | 91.60M | 106.52M | 109.90M | 103.69M | 112.40M |
| Net Income Ratio | 7.59% | 8.99% | 9.34% | 9.38% | 10.40% |
| EPS | 1.38 | 1.69 | 1.74 | 1.89 | 2.04 |
| EPS Diluted | 1.38 | 1.68 | 1.74 | 1.89 | 2.04 |
| Weighted Avg Shares Out | 66.24M | 63.15M | 63.00M | 54.86M | 55.10M |
| Weighted Avg Shares Out (Dil) | 66.38M | 63.59M | 63.00M | 54.86M | 55.10M |
Source: https://incomestatements.info
Category: Stock Reports